Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

Cardiovascular disease

A united vision for cardiovascular–kidney–metabolic health

Improved understanding of the interrelated nature of cardiovascular, kidney and metabolic (CKM) health, the development of novel risk prediction equations, and the availability of powerful new therapies provide an opportunity to change the course of CKM health. Achieving such change at a population level will require additional advances to deliver equitable interdisciplinary care.

This is a preview of subscription content, access via your institution

Access options

Buy this article

Prices may be subject to local taxes which are calculated during checkout

References

  1. Ndumele, C. E. et al. Cardiovascular-kidney-metabolic health: a presidential advisory from the American Heart Association. Circulation 148, 1606–1635 (2023).

    Article  PubMed  Google Scholar 

  2. Khan, S. S. et al. Novel prediction equations for absolute risk assessment of total cardiovascular disease incorporating cardiovascular-kidney-metabolic health: a scientific statement from the American Heart Association. Circulation 148, 1982–2004 (2023).

    Article  PubMed  Google Scholar 

  3. Khan, S. S. et al. Development and validation of the American Heart Association Predicting Risk of Cardiovascular Disease EVENTs (PREVENT) equations. Circulation (2023).

  4. Bakris, G. L. et al. Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes. N. Engl. J. Med. 383, 2219–2229 (2020).

    Article  CAS  PubMed  Google Scholar 

  5. Brosius, F. C. et al. Transforming the care of patients with diabetic kidney disease. Clin. J. Am. Soc. Nephrol. 16, 1590–1600 (2021).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Kosiborod, M. N. et al. Semaglutide in patients with heart failure with preserved ejection fraction and obesity. N. Engl. J. Med. 389, 1069–1084 (2023).

    Article  CAS  PubMed  Google Scholar 

  7. Zinman, B. et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N. Engl. J. Med. 373, 2117–2128 (2015).

    Article  CAS  PubMed  Google Scholar 

  8. Vyas, D. A., Eisenstein, L. G. & Jones, D. S. Hidden in plain sight - reconsidering the use of race correction in clinical algorithms. N. Engl. J. Med. 383, 874–882 (2020).

    Article  PubMed  Google Scholar 

  9. Waters, H. & Graf, M. America’s Obesity Crisis. The Health and Economic Costs of Excess Weight (Milken Institute, 2018).

  10. AHA. Get With The Guidelines. heart.org, https://www.heart.org/en/professional/quality-improvement/get-with-the-guidelines (2024).

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Susan E. Quaggin.

Ethics declarations

Competing interests

The authors declare no competing interests.

Additional information

Related links

PREVENT online calculator: https://professional.heart.org/en/guidelines-and-statements/prevent-calculator

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Quaggin, S.E., Magod, B. A united vision for cardiovascular–kidney–metabolic health. Nat Rev Nephrol 20, 273–274 (2024). https://doi.org/10.1038/s41581-024-00812-6

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41581-024-00812-6

Search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing